Forty years of HIV research inspires the development of SARS-CoV-2 therapy
Open Access
- 23 October 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 15 (10)
Abstract
Almost four decades ago, the characterization of the human immunodeficiency virus type 1 (HIV-1) genome with the participation of the Haseltine laboratory at Harvard Medical School ( Ratner et al., 1985) ushered in the antiretroviral era and established the framework for the genomic- and later multiple omics-based development of targeted antiviral drugs. Battles with pandemic HIV-1 taught us that multitargeted combination antiviral therapy is needed to control pathogens that rapidly adapt to selective pressures from the immune system, vaccines, and therapeutic monoclonal antibodies, such as pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains. The development of therapeutics active against all SARS-CoV-2 variants of concern and human coronaviruses could be expedited by taking approaches used for developing the inhibitors of HIV-1 integrase and capsid as well as hepatitis C virus, such as rationale-based drug design aided by generative artificial intelligence and chemistry. Here, we provide examples of cross-pollination between researches on HIV-1 and SARS-CoV-2 to identify potential SARS-CoV-2 therapeutic targets at various lifecycle stages.Keywords
This publication has 20 references indexed in Scilit:
- Interactomics: Dozens of Viruses, Co-evolving With Humans, Including the Influenza A Virus, may Actively Distort Human AgingMolecular Biology and Evolution, 2023
- Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing AgentsNon-Coding RNA, 2023
- Novel perspectives on antisense transcription in HIV-1, HTLV-1, and HTLV-2Frontiers in Microbiology, 2022
- Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolutionNature, 2022
- SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2DCell Reports, 2022
- Quinolizidines as Novel SARS-CoV-2 Entry InhibitorsInternational Journal of Molecular Sciences, 2022
- Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2Frontiers in Bioengineering and Biotechnology, 2022
- Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery coreNature Communications, 2022
- Circulating Exosomes Are Strongly Involved in SARS-CoV-2 InfectionFrontiers in Molecular Biosciences, 2021
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985